FAST-Funded Research Leads To $1.1 Million Grant

Additional Gene Therapy Approach For Angelman Syndrome Explored By Paula Evans The Foundation for Angelman Syndrome Therapeutics (FAST) is delighted to announce that research FAST has funded, through the support of our donors, has secured a $1.1 Million grant from the California Institute for Regenerative Medicine, to develop an additional gene therapy approach for the […]

Towards Therapeutics – The FIRE Team Series, Part I

Edwin Weeber, Ph.D. is a Professor in the Department of Molecular Pharmacology and Physiology and the Chief Scientific Officer at the University of South Florida Health Byrd Alzheimer Institute. Dr. Weeber also serves on the Foundation for Angelman Syndrome Therapeutic’s (FAST) Scientific Advisory Board and the FAST Integrative Research Environment (FIRE) Initiative.   The FIRE […]

Collaborating for Clinical Trials

Stakeholders meet to develop Biomarkers and Outcome Measures for clinical trials in Angelman Syndrome We are thrilled to announce that the Angelman Syndrome community has reached one of the most significant advancements in the field of Angelman Syndrome (AS) to date: representatives from six pharmaceutical companies, scientists, clinicians, therapists, parents, private industry, the Foundation for […]

Ketone esters for the treatment of seizures in AS – clinical trial coming soon!

Medical foods as an effective approach to management of Angelman Syndrome The following is a recount of a presentation about using therapeutic ketones (KES) through oral supplementation to improve the symptoms of Angelman Syndrome, presented by Angela Poff, Mike McCandless,  Donna Herber from Disruptive Nutrition at the FAST Summit in Chicago in December 2015. This is […]

FAST Research Series

Read our regular series summarizing lectures presented on Friday December 4th, 2015, the first day of the 2015 FAST Global Summit. This series will be focused on research, pre-clinical, and future clinical trials